You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Peptide Receptor Radionuclide Therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy Trial in Rotterdam (olaparib)

Recruiting
  • Neuroendocrine Tumors
  • Peptide Receptor Radionuclide Therapy
  • Rotterdam, South Holland, Netherlands
    Erasmus MC
May 19, 2023

Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma Trial (Lu-177 DOTATATE

Not yet recruiting
  • Bronchial and Thymic Neuroendocrine Tumour
  • +3 more
  • Lu-177 DOTATATE (Lutathera®)
  • (no location specified)
Nov 1, 2023

Metastatic Malignant Tumor in the Liver, Neuroendocrine Tumor Trial in San Francisco (procedure, biological, device)

Recruiting
  • Metastatic Malignant Neoplasm in the Liver
  • Neuroendocrine Neoplasm
  • Arterial Embolization
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Dec 22, 2022

AminoMedixTM for Kidney Protection During Radionuclide Therapy

Completed
  • Radiation Nephropathy
    • (no location specified)
    Mar 22, 2023

    Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine

    Not yet recruiting
    • Digestive System Neuroendocrine Tumor G1
    • +5 more
    • Tumor Debulking
    • +5 more
    • Nashville, Tennessee
      Vanderbilt University/Ingram Cancer Center
    Aug 23, 2023

    HRQoL During PRRT in Patients With NETs

    Completed
    • Neuroendocrine Tumors
    • +2 more
      • (no location specified)
      Jun 16, 2022

      Pancreatic Neuroendocrine Tumor, Pancreas Cancer Trial in Chicago (cytoreductive surgery, Lutathera - a small molecule used in

      Not yet recruiting
      • Pancreatic Neuroendocrine Tumor
      • Pancreas Cancer
      • cytoreductive surgery
      • +2 more
      • Chicago, Illinois
        The University of Chicago
      Nov 8, 2022

      Merkel Cell Carcinoma Trial (Pembrolizumab, Lutetium Lu 177 dotatate)

      Not yet recruiting
      • Merkel Cell Carcinoma
      • (no location specified)
      Oct 12, 2022

      Pancreatic Neuroendocrine Tumor Trial in Milano (peptide receptor radionuclide therapy with Y-90-DOTATOC)

      Recruiting
      • Pancreatic Neuroendocrine Tumor
      • peptide receptor radionuclide therapy with Y-90-DOTATOC
      • Milano, Italy
      • +1 more
      Sep 30, 2022

      Neuroblastoma Trial in Lille, Lyon, Toulouse (PRRT with 177Lu-DOTATATE)

      Not yet recruiting
      • Neuroblastoma
      • PRRT with 177Lu-DOTATATE
      • Lille, France
      • +2 more
      Nov 8, 2022

      (PRRT) for the Treatment of Neuroendocrine Tumors

      Enrolling by invitation
      • Neuroendocrine Tumors
      • Peptide Receptor Radionuclide Therapy
      • Dallas, Texas
        Methodist Dallas Medical Center
      Oct 27, 2021

      Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea Trial in Iowa City (Telotristat ethyl, Peptide Receptor Radionuclide

      Withdrawn
      • Neuroendocrine Tumors
      • +2 more
      • Telotristat ethyl
      • +2 more
      • Iowa City, Iowa
        University of Iowa Hospital and Clinics
      Feb 9, 2022

      Nasopharyngeal Carcinoma Trial in Xiamen (177Lu-EB-LM3 1, 177Lu-EB-LM3 2)

      Recruiting
      • SSTR2-positive Tumors
      • 177Lu-LNC1010 1
      • +2 more
      • Xiamen, China
        The First Affiliated Hospital of Xiamen University
      Nov 20, 2022

      Semi-automated Segmentation Methods of SSTR PET for Dosimetry

      Not yet recruiting
      • Refractory Meningioma
      • To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
      • (no location specified)
      Sep 8, 2022

      Advanced Pancreatic Cancer and Cholangiocarcinoma Trial in Hangzhou (PRRT with 177Lu-EB-FAPI)

      Recruiting
      • Advanced Pancreatic Cancer and Cholangiocarcinoma
      • PRRT with 177Lu-EB-FAPI
      • Hangzhou, Zhejiang, China
        First Affiliated Hospital of Zhejiang University
      Oct 10, 2023

      Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma Trial in United States (67Cu-SARTATE, 64Cu-SARTATE)

      Recruiting
      • Neuroblastoma
      • +2 more
      • Phoenix, Arizona
      • +8 more
      Jun 29, 2022

      Neuroendocrine Tumors Trial in Portland (Cabozantinib, Lu-177)

      Not yet recruiting
      • Neuroendocrine Tumors
      • Portland, Oregon
        Providence Portland Cancer Institute - Franz Clinic
      Feb 10, 2022

      Neuroendocrine Tumors Trial in Melbourne (Talazoparib)

      Recruiting
      • Neuroendocrine Tumors
      • Melbourne, Victoria, Australia
        Peter MacCallum Cancer Centre
      Sep 20, 2021

      Gastroenteropancreatic Neuroendocrine Tumor Trial in Stanford (Lutathera, Gallium 68 Dotatate, Computed Tomography (CT))

      Suspended
      • Gastroenteropancreatic Neuroendocrine Tumor
      • Stanford, California
        Stanford Cancer Institute Palo Alto
      Sep 21, 2022

      Neuroendocrine Tumors Trial in Iowa City ([90]Y-DOTATOC)

      Suspended
      • Neuroendocrine Tumors
      • Iowa City, Iowa
        The Holden Comprehensive Cancer Center
      Mar 8, 2022

      Metastatic Merkel Cell Carcinoma Trial in Australia (Avelumab, External Beam Radiation Therapy (EBRT), Lutetium-177

      Recruiting
      • Metastatic Merkel Cell Carcinoma
      • Sydney, New South Wales, Australia
      • +5 more
      Apr 21, 2021

      Neuroendocrine Tumors Trial in Worldwide (177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine

      Recruiting
      • Neuroendocrine Tumors
      • 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
      • +4 more
      • Palo Alto, California
      • +30 more
      Dec 14, 2022

      Gastro-entero-pancreatic Neuroendocrine Tumors Trial in Meldola (Capecitabine, Lu-PRRT, SS-LAR)

      Active, not recruiting
      • Gastro-entero-pancreatic Neuroendocrine Tumors
      • Meldola, FC, Italy
        Irst Irccs
      Feb 25, 2021

      Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT) Trial in Ferrara (Lutetium-177 (177Lu)-DOTATOC, Yttrium-90

      Recruiting
      • Neuroendocrine Tumors
      • Peptide Receptor Radionuclide Therapy (PRRT)
      • Lutetium-177 (177Lu)-DOTATOC
      • +4 more
      • Ferrara, Italy
        University Hospital of Ferrara
      Mar 5, 2021

      Neuroendocrine Tumors Trial in Meldola (177Lu-DOTATATE 25.9 GBq activity, 177Lu-DOTATATE 18.5 GBq activity)

      Active, not recruiting
      • Neuroendocrine Tumors
      • 177Lu-DOTATATE 25.9 GBq activity
      • 177Lu-DOTATATE 18.5 GBq activity
      • Meldola, FC, Italy
        Irst Irccs
      Feb 25, 2021